FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
Geist William
(Last) (First) (Middle)
614 MCKINLEY PLACE NE
(Street)
MINNEAPOLIS MN 55413
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT, PROTEIN SCIENCES
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2026   M   6,416 A $ 0 26,919 D  
Common Stock 08/15/2026   F   1,976 D $ 72.4 24,943 D  
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $ 100.39               (2) 02/01/2029 Common Stock 15,912   15,912 D  
Stock Options (Right to Buy) $ 94.52               (2) 08/15/2029 Common Stock 29,600   29,600 D  
Performance Restricted Stock Units (1) 08/15/2026   M     567   (3)   (3) Common Stock 567 $ 0 8,507 D  
Performance Restricted Stock Units (1) 08/15/2026   D     8,507   (3)   (3) Common Stock 8,507 $ 0 0 D  
Performance Stock Options (Right to Buy) $ 84.61 08/15/2026   D     22,898   (5)   (5) Common Stock 22,898 $ 0 1,526 D  
Stock Options (Right to Buy) $ 84.61               (4) 08/15/2030 Common Stock 30,059   30,059 D  
Performance Restricted Stock Units (1)               (6)   (6) Common Stock 15,738   15,738 D  
Restricted Stock Units (1) 08/15/2026   M     2,623   (7)   (7) Common Stock 2,623 $ 0 2,623 D  
Stock Options (Right to Buy) $ 74.91               (8) 08/15/2034 Common Stock 21,204   21,204 D  
Performance Restricted Stock Units (1)               (9)   (9) Common Stock 19,355   19,355 D  
Restricted Stock Units (1) 08/15/2026   M     3,226   (10)   (10) Common Stock 3,226 $ 0 6,452 D  
Stock Options (Right to Buy) $ 53.6               (11) 08/15/2035 Common Stock 24,758   24,758 D  
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
2. 100% vested.
3. On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited.
4. Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.
5. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,526 performance options. The remainder of the performance options were forfeited.
6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. 2,623 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
8. Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
9. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
10. 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
11. Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028.
/s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to Power of Attorney previously filed 08/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.